Redaktionelle Informationen

Trinseo Evolves Beyond PC to Include Styrenics for Medical Applications

Biocompatible Polystyrene, Glass-Filled PC, ABS Featured at COMPAMED 2016

HORGEN, Switzerland - Monday, November 14, 2016

Trinseo (NYSE: TSE), the global materials company and manufacturer of plastics, latex binders and synthetic rubber, will introduce a broadened medical portfolio when it exhibits at the COMPAMED trade show in Dusseldorf, Germany from November 14 – 17, 2016 at booth L39 in Hall 8B.

Trinseo continues to expand its plastics portfolio for medical applications beyond polycarbonate-based compounds to medical grade styrenics. This includes its newest plastic, STYRON™ 2678 MED Polystyrene Resin, a general purpose polystyrene (GPPS) offering the versatility of polystyrene with the assurance of biocompatibility and a three year extended notification of change. STYRON™ 2678 MED is ideal for clear packaging, diagnostic components, petri dishes and test kit housings.

Trinseo will continue to highlight its MAGNUM™ ABS Resins and EMERGE™ Advanced Resins for applications including single- and multiple-use drug delivery devices and equipment housings. The company’s ABS offers the advantage of mass polymerization technology which results in lower residual monomers, exceptional purity, brilliant whiteness, and lot-to-lot consistency.

“Companies need plastics that support today’s trends in medical device design such as light weighting, aesthetic appeal, durability and cost reduction,” said Wassim Berrak, European medical business manager. “Trinseo’s portfolio of biocompatible plastics ranging from transparent polystyrene to ABS to glass-filled polycarbonate to chemical resistant blends offers customers the variety they seek along with the ability to choose materials having very specific requirements, most cost effectively.”                                                                                                                                  

Trinseo supports the medical market through its Consumer Essential Markets (CEM) unit, part of its Performance Plastics business.  Last month, Trinseo achieved a milestone when it became ISO 13485 certified as “manufacturer and developer of medical compounds” at its medical production facilities in Stade, Germany and Hsinchu, Taiwan and also in ancillary functions including Research & Development, Technical Service & Development, Sales, Quality and Procurement. This certification indicates Trinseo’s commitment to the medical devices business and strategic alignment with its customers’ objectives. 

Earlier this year the company introduced a new production and fulfillment model featuring custom medical compounding in Asia Pacific complementing medical compounding in North America and Europe. These facilities are sourced with polycarbonate base resins from Trinseo’s highest quality, medically-equivalent resins produced in Germany and also by its joint venture partner, Sumika Styron Polycarbonate Limited, in Japan.

To arrange a meeting with Trinseo onsite at COMPAMED 2016 contact Paula Biskup, global business communications manager.

About Trinseo

Trinseo (NYSE:TSE) is a global materials solutions provider and manufacturer of plastics, latex binders, and synthetic rubber with a focus on delivering innovative, sustainable, and value-creating products that are intrinsic to our daily lives. Trinseo is dedicated to making a positive impact on society by partnering with like-minded stakeholders, and supporting the sustainability goals of our customers in a wide range of end-markets including automotive, consumer electronics, appliances, medical devices, packaging, footwear, carpet, paper and board, building and construction, and tires. Trinseo had approximately $3.8 billion in net sales with 2,700 employees globally in 2019. For more information, please visit:

Note on Forward-Looking Statements

This press release may contain “forward-looking statements” including, without limitation, statements concerning plans, objectives, goals, projections, expectations, strategies, future events or performance, and underlying assumptions and other statements, which are not statements of historical facts. Forward-looking statements may be identified by the use of words like “expect,” “estimate,” “will,” “may,” or expressions of similar meaning. Forward-looking statements reflect management’s evaluation of information currently available and are based on the Company’s current expectations and assumptions regarding the impact from the COVID-19 pandemic, the Company’s business, the economy and other future conditions. Specific factors that could cause future results to differ from those expressed by the forward-looking statements include, but are not limited to, risks related to the ongoing impact of the COVID-19 pandemic and those discussed in the Company’s Annual Report for the year ended December 31, 2019 filed with the Securities and Exchange Commission (“SEC”), in subsequent Quarterly Reports on Form 10-Q and in other filings and furnishings made by the Company with the SEC from time to time. Other unknown or unpredictable factors could also have material adverse effects on the Company’s performance. As a result of these or other factors, the Company’s actual results may differ materially from those contemplated by the forward-looking statements. The forward-looking statements included in this press release are made only as of the date hereof and are not a guarantee of future performance. The Company undertakes no obligation to publicly update or revise any forward-looking statement as a result of new information, future events or otherwise, except as otherwise required by law.

Redaktionelle Informationen

Trinseo News

November 9 - November 10, 2020 Plastic Free World Virtual Summit Location - Virtual Business alignment - Plastics

Exklusive Trinseo-Inhalte erhalten

Seien Sie der Erste, der über neue Produktinformationen, Unternehmensnachrichten und weitere Trinseo-Updates bequem per E-Mail informiert wird!